NO2646011T3 - - Google Patents

Info

Publication number
NO2646011T3
NO2646011T3 NO11844637A NO11844637A NO2646011T3 NO 2646011 T3 NO2646011 T3 NO 2646011T3 NO 11844637 A NO11844637 A NO 11844637A NO 11844637 A NO11844637 A NO 11844637A NO 2646011 T3 NO2646011 T3 NO 2646011T3
Authority
NO
Norway
Application number
NO11844637A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46172302&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2646011(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of NO2646011T3 publication Critical patent/NO2646011T3/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
NO11844637A 2010-12-03 2011-12-02 NO2646011T3 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41935410P 2010-12-03 2010-12-03
PCT/US2011/063170 WO2012075453A1 (en) 2010-12-03 2011-12-02 Methods for reducing binge or compulsive eating

Publications (1)

Publication Number Publication Date
NO2646011T3 true NO2646011T3 (hr) 2018-01-13

Family

ID=46172302

Family Applications (1)

Application Number Title Priority Date Filing Date
NO11844637A NO2646011T3 (hr) 2010-12-03 2011-12-02

Country Status (26)

Country Link
US (2) US20130252995A1 (hr)
EP (1) EP2646011B1 (hr)
JP (1) JP2014508717A (hr)
KR (1) KR20140035319A (hr)
CN (1) CN103298462A (hr)
AR (2) AR084093A1 (hr)
AU (3) AU2011336298B2 (hr)
BR (1) BR112013015957B1 (hr)
CA (1) CA2819003A1 (hr)
CL (1) CL2013001565A1 (hr)
CY (1) CY1119560T1 (hr)
DK (1) DK2646011T3 (hr)
ES (1) ES2647232T3 (hr)
HR (1) HRP20171678T1 (hr)
HU (1) HUE034641T2 (hr)
IL (1) IL226483A0 (hr)
LT (1) LT2646011T (hr)
MX (1) MX350304B (hr)
NO (1) NO2646011T3 (hr)
PL (1) PL2646011T3 (hr)
PT (1) PT2646011T (hr)
RS (1) RS56548B1 (hr)
RU (1) RU2620913C2 (hr)
SI (1) SI2646011T1 (hr)
TW (2) TWI536986B (hr)
WO (1) WO2012075453A1 (hr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1784221B (zh) 2003-04-29 2010-07-07 奥雷西根治疗公司 影响体重减轻的组合物
MX337422B (es) 2005-11-22 2016-03-04 Orexigen Therapeutics Inc Composiciones y metodos para incrementar la sencibilidad a la insulina.
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
KR20140088619A (ko) 2006-11-09 2014-07-10 오렉시젠 세러퓨틱스 인크. 단위 용량 팩키지
JP2011521973A (ja) 2008-05-30 2011-07-28 オレキシジェン・セラピューティクス・インコーポレーテッド 内臓脂肪の状態を処置するための方法
KR101841442B1 (ko) 2010-01-11 2018-03-23 오렉시젠 세러퓨틱스 인크. 주우울증 환자들에 있어서 체중 감량 치료를 제공하는 방법
CA2875056C (en) 2012-06-06 2024-03-26 Orexigen Therapeutics, Inc. Methods of treating overweight and obesity
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2197250C2 (ru) * 2000-10-30 2003-01-27 Соколовский Сергей Ростиславович Способ лечения наркоманий
CN1784221B (zh) 2003-04-29 2010-07-07 奥雷西根治疗公司 影响体重减轻的组合物
US20070099947A1 (en) * 2005-11-03 2007-05-03 Alkermes, Inc. Methods and compositions for the treatment of brain reward system disorders by combination therapy
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
KR20140088619A (ko) 2006-11-09 2014-07-10 오렉시젠 세러퓨틱스 인크. 단위 용량 팩키지
TWI609702B (zh) 2006-11-09 2018-01-01 歐瑞根治療有限公司 層狀醫藥調配物
GB2447949B (en) * 2007-03-29 2010-03-31 Renasci Consultancy Ltd A method for identifying a compound for treating a disorder or condition associated with dysfunction of monoamine neurotransmission
WO2009035473A2 (en) * 2007-09-13 2009-03-19 Sanfilippo Louis C Method of treating binge eating disorder, obesity resulting from binge eating behavior and depressive disorders
WO2009080691A2 (en) * 2007-12-20 2009-07-02 Neurosearch A/S Pharmaceutical composition comprising tesofensine or its analogue and an anti-obesity compound
CA2817071C (en) * 2010-11-08 2018-04-24 Omeros Corporation Treatment of addiction and impulse-control disorders using pde7 inhibitors

Also Published As

Publication number Publication date
CA2819003A1 (en) 2012-06-07
AU2017202793A1 (en) 2017-05-18
IL226483A0 (en) 2013-07-31
TWI536986B (zh) 2016-06-11
HUE034641T2 (en) 2018-02-28
RS56548B1 (sr) 2018-02-28
EP2646011A4 (en) 2014-04-23
SI2646011T1 (en) 2018-01-31
AU2011336298A1 (en) 2013-07-11
MX2013006070A (es) 2013-07-29
WO2012075453A1 (en) 2012-06-07
AU2018203921A1 (en) 2018-06-21
TW201228659A (en) 2012-07-16
AU2011336298B2 (en) 2017-03-02
HRP20171678T1 (hr) 2017-12-15
BR112013015957A2 (pt) 2019-10-29
AR124497A2 (es) 2023-04-05
AR084093A1 (es) 2013-04-17
JP2014508717A (ja) 2014-04-10
RU2620913C2 (ru) 2017-05-30
RU2013127420A (ru) 2015-01-10
CL2013001565A1 (es) 2014-04-04
TW201735912A (zh) 2017-10-16
MX350304B (es) 2017-09-04
LT2646011T (lt) 2017-11-10
ES2647232T3 (es) 2017-12-20
DK2646011T3 (da) 2017-11-20
KR20140035319A (ko) 2014-03-21
US20130252995A1 (en) 2013-09-26
PT2646011T (pt) 2017-11-17
EP2646011A1 (en) 2013-10-09
AU2017202793B2 (en) 2018-03-08
CN103298462A (zh) 2013-09-11
CY1119560T1 (el) 2018-03-07
PL2646011T3 (pl) 2018-01-31
BR112013015957B1 (pt) 2021-07-20
EP2646011B1 (en) 2017-08-16
US20210283126A1 (en) 2021-09-16

Similar Documents

Publication Publication Date Title
BR112013008959A2 (hr)
BR112012031500A2 (hr)
BR112012029986A2 (hr)
BR112012030039A2 (hr)
BR112012028408A2 (hr)
BR112012026492A2 (hr)
BR112012027808A2 (hr)
BR112012024897A2 (hr)
BR112012025307A2 (hr)
BR112012026946A2 (hr)
BR112012025482A2 (hr)
BR112013006400A2 (hr)
BR112012031826A2 (hr)
BR112012028186A2 (hr)
BR112012025577A2 (hr)
BR112012027015A2 (hr)
BR112012025308A2 (hr)
BR112012027945A2 (hr)
BR112012024872A2 (hr)
BR112013010949A2 (hr)
BR112013003284A2 (hr)
BR112013002646A2 (hr)
BR112012026403A2 (hr)
BR112013006825A2 (hr)
BR112012028859A2 (hr)